Regeneron Pressed About Pending COVID-19 Antibody EUA
Q3 Revenues Were Up 32%, But Main Topic Remains EUA
Executive Summary
CEO Len Schleifer said he does not know the timeline for when the US FDA could authorize REGN-COV2 but expects to hear from the agency soon.